TFF Pharma To Begin Human Trial For Inhaled COVID-19 Therapy In Canada

TFF Pharmaceuticals Inc TFFP has received approval from Health Canada to begin a Phase 1 trial of a dry powder formulation of niclosamide, an antiviral treatment with the potential to address COVID-19 and other infectious diseases.
TFF Pharmaceuticals anticipates dosing to begin in November, with enrollment to complete by early Q1 2022.
First approved by the FDA in 1982, niclosamide is an oral anthelmintic drug and is included in the World Health Organization's list of essential medicines.
The Phase 1 study will consist of a Single Ascending Dose (SAD) phase with single doses of 0.5, 2, and 6 mg in three cohorts of healthy volunteers.
The Multiple Ascending Dose (MAD) phase in two cohorts of healthy volunteers will receive doses of 3 and 6 mg, respectively, every 12 hours (BID dosing) for five days.
Related: Augmenta - TFF Pharma's COVID-19 Antibody Shows Preclinical Activity Against Delta Variant.
Price Action: TFFP shares are up 1.41% at $7.93 during the market session on the last check Thursday.